Development of curcumin solid lipid nanoparticle and assessment of pharmacokinetics and brain availability in Wistar rats - See more at: http://nutraceuticals.pharmaceuticalconferences.com/scientific-program.php?day=1&sid=805&date=2015-07-13#sthash.cAtc3Kjn.dpuf
CU5b) to be optimized formulation based on the particle size (127 nm), drug entrapment (90.40%) and in vitro drug release (82% at the end of 24 hr) analysis. The optimized ... form of SLN. The curcumin & SLN curcumin in…

